5 Key Takeaways

• 1

  The success of oral GLP-1 receptor agonists depends on matching peptide efficacy and safety while ensuring scalable manufacturing.

• 2

  Peptide GLP-1s face production limits that small molecules could potentially overcome, offering cheaper and more efficient manufacturing options.

• 3

  Oral GLP-1 small molecules must address low solubility and permeability to improve absorption and reduce the required API per dose.

• 4

  Manufacturing economics and operational efficiency are crucial for the success of small molecules in the GLP-1 market.

• 5

  Both peptide and small molecule GLP-1s may coexist in the future, with the focus on disciplined industrial chemistry for production.